Rapid and specific influenza virus detection by functionalized magnetic nanoparticles and mass spectrometry
© Chou et al; licensee BioMed Central Ltd. 2011
Received: 6 July 2011
Accepted: 16 November 2011
Published: 16 November 2011
The timely and accurate diagnosis of specific influenza virus strains is crucial to effective prophylaxis, vaccine preparation and early antiviral therapy. The detection of influenza A viruses is mainly accomplished using polymerase chain reaction (PCR) techniques or antibody-based assays. In conjugation with the immunoassay utilizing monoclonal antibody, mass spectrometry is an alternative to identify proteins derived from a target influenza virus. Taking advantage of the large surface area-to-volume ratio, antibody-conjugated magnetic nanoparticles can act as an effective probe to extract influenza virus for sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) and on-bead mass spectrometric analysis.
Iron oxide magnetic nanoparticles (MNP) were functionalized with H5N2 viral antibodies targeting the hemagglutinin protein and capped with methoxy-terminated ethylene glycol to suppress nonspecific binding. The antibody-conjugated MNPs possessed a high specificity to H5N2 virus without cross-reactivity with recombinant H5N1 viruses. The unambiguous identification of the captured hemagglutinin on magnetic nanoparticles was realized by SDS-PAGE visualization and peptide sequence identification using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
The assay combining efficient magnetic separation and MALDI-MS readout offers a rapid and sensitive method for virus screening. Direct on-MNP detection by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) provided high sensitivity (~103 EID50 per mL) and a timely diagnosis within one hour. The magnetic nanoparticles encapsulated with monoclonal antibodies could be used as a specific probe to distinguish different subtypes of influenza.
Influenza remains a major health problem for humans and animals. The recent cross-species transmission of avian influenza viruses to humans has raised a great concern for the possible global pandemic threat if the viruses become transmissible among humans.
Influenza viruses can be classified into types A, B and C. These subtypes are further designated according to the serological cross-reactivity of the antibodies against hemagglutinin (HA) and neuraminidase (NA), which are the most important glycoproteins on the surface of influenza virus with critical roles in virus infection and transmission. To date, 16 HA (H1-H16) and 9 NA (N1-N9) subtypes in influenza A viruses have been isolated from avian species. HA is translated as a single polyprotein, HA0, which exists in a trimeric assembly [1, 2]. The transmembrane protein HA0 consists of two polypeptide chains, HA1 and HA2, linked by inter-chain disulfide bonds. For viral activation, HA0 must undergo an enzymatic cleavage to give two functional subunits, HA1 and HA2[1, 2]. Highly pathogenic avian influenza viruses, such as H5N1, contain many basic amino acid residues in the cleavage site of HA0 and are thus easily activated by trypsin and other proteases for systemic infection [1, 2].
At present, four drugs are approved for influenza prophylaxis and treatment [3–5]: amantadine and rimantadine act as M2 ion channel blockers, and Tamiflu™ (the phosphate salt of oseltamivir) and Relenza™ (zanamivir) inhibit the activity of NA. For the most effective treatment, these anti-influenza drugs are recommended for use within 48 h of the onset of influenza symptoms because proliferation of the virus reaches a peak after 2 days of infection. Thus, timely and accurate diagnosis of specific influenza virus strains is crucial for effective prophylaxis, vaccine preparation and early antiviral therapy.
The detection of influenza A viruses is mainly accomplished using polymerase chain reaction (PCR) techniques or antibody-based assays to identify the relatively abundant nucleoproteins (NP) [6–13]. Because NP is only a type-specific protein, subtype- or strain-specific diagnosis cannot be achieved. For the specific detection of influenza viruses using real-time reverse transcription-polymerase chain reaction (rRT-PCR) [6–9], choosing proper primer pairs for subtyping becomes critical. Although sequence-based diagnosis often shows high sensitivity, the experimental procedures are tedious and may give false results.
According to a recent survey , the commercially available influenza diagnostic kits based on rRT-PCR can be used to detect H1N1 virus with a limit of detection in the range of 104.5-105.5 TCID50 (50% tissue culture infective dose) per mL. However, a negative result does not rule out possible infection with influenza virus due to the overall low sensitivity (40-69%) of the diagnostic kits . In contrast, an antigen capture immunoassay with specific monoclonal antibodies [10–13] is often utilized in rapid influenza diagnostic tests. An investigation into the commercially available test kits indicated that 104.7 mean embryo lethal dose (ELD50)/mL of avian influenza viruses in allantoic fluid can be detected by an antigen capture immunoassay .
The low sensitivity in antigen tests may be problematic in dealing with untreated samples due to nonspecific interactions with other proteins. The antigen-capture enzyme-linked immunosorbent assay (ELISA) has been explored to distinguish subtypes of influenza viruses with better sensitivity than immunoassays . However, ELISA is time consuming and usually takes prolonged times (~ 12 hours) to provide results.
Alternative methods have been investigated for viral detection, including surface plasmon resonance , multiplexed flow cytometry , quartz-crystal microbalance , mass spectrometry [17–19], and microarrays [20–26]. With the power of peptide sequencing and database searches for unknown protein identification, however, mass spectrometry has been considered as one of the gold standard methods for protein analysis due to its low detection limit, rich structural information, and, most importantly, high accuracy. The Yip group was one of the first to integrate affinity capture techniques with direct mass spectrometric detection of target proteins from a complex mixture . The concept was advanced further by Nelson and coworkers in the development of a mass spectrometric immunoassay (MSIA) using affinity pipette tips to selectively detect proteins and their variants [28–30]. Despite these existing methodologies, to our knowledge the application of affinity-based mass spectrometric methods for detection and identification of flu strains remains unexplored.
In combination with immunoassays utilizing monoclonal antibodies, mass spectrometry is especially useful for the identification of proteins derived from a target influenza virus. Mass spectrometry is not only applicable to confirm the subtype of virus but is also a powerful tool for the identification of the antigenic determinants on the viral HA [17–19]. Prior enrichment of the viral antigen is often utilized to improve the detection sensitivity and the coverage of peptide sequence identification in the mass spectra. An effective method for viral antigen enrichment using surface functionalized magnetic nanoparticles is pursued in this study.
Taking advantage of the large surface area-to-volume ratio and the unique chemical and physical properties of nanoparticles, a considerable number of studies on surface functionalization have been reported for biomedical applications. Among the various types of nanoparticles, magnetic nanoparticles (MNPs) have attracted increasing attention for the advantage of efficient separation from complex mixtures with a magnetic field [31–39]. This unique characteristic of MNPs surpasses traditional solvent intensive and time-consuming purification methods.
As demonstrated in our previous study [36, 37], antibody-conjugated MNPs with proper surface protection act as efficient affinity probes for the rapid extraction of target proteins from human plasma. Because HA proteins are located on the surface of influenza viruses, MNPs modified with HA antibodies can be envisioned as an effective nanosensor for rapid detection of influenza viruses. Through this MNP-assisted mass spectrometry-based immunoassay, we expect to develop a simple and fast virus screening assay with unambiguous identification. H5N2, an avian influenza virus with low pathogenicity, and recombinant H5N1 pseudo-viruses were utilized as proof-of-concept model systems to evaluate the assay performance in terms of sensitivity and specificity. The data demonstrated the combined use of the antibody-MNP and MALDI-MS methods for the sensitive detection of influenza viruses and rapid screening of virus subtypes. The specificity of HA enrichment was confirmed by sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) and peptide mass sequencing using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Results and discussion
• Preparation and characterization of ethyleneglycol-protected anti-HA antibody-conjugated magnetic nanoparticles
• Extraction of HA proteins by antibody-conjugated magnetic nanoparticles and on-bead MALDI-MS analysis
Our strategy for isolation and identification of HA proteins by AbH5N2@Fe3O4 MNP is depicted in Figure 1B. Briefly, the AbH5N2@Fe3O4 MNPs were incubated with virus lysate in a chosen buffer. After incubation, the newly formed complexes containing AbH5N2@Fe3O4 MNPs and extracted HA (designated as HA-MNP complexes) were readily isolated by applying a magnet. The nonspecifically bound proteins were washed away, and the HA-MNP complexes were directly analyzed by either SDS-PAGE or MALDI-TOF MS. It was noted that both assays could be performed in an efficient manner without commonly required elution and desalting; our method thus reduced the time required for assay.
It was also noted that the incubation buffer was crucial to this experiment. Virus lysate in allantoic fluid has a complex composition, containing not only the H5N2 virus, but also other proteins abundant in the culture medium. Non-specific adsorption from these abundant proteins often interferes with immunoassays. Furthermore, HA is a trimeric transmembrane protein; thus detergent or salts are required to properly solubilize the hydrophobic protein and to avoid protein-protein aggregation. The effect of using different buffers on the specificity of affinity extraction was therefore evaluated. RIPA buffer, which is commonly used as a lysis buffer for immunoprecipitation assays, showed the best removal of abundant proteins capable of nonspecific interactions with AbH5N2@Fe3O4 MNPs. Consequently, isolation of the viral HA protein by AbH5N2@Fe3O4 MNPs was more efficient in RIPA buffer than in water or PBS buffer.
MALDI-MS can be combined with a biologically active probe to rapidly and specifically detect proteins of interest. To explore the capability of on-MNP readout by MALDI-MS, a protein pool mimicking a complex biological medium was prepared in 60 μL of PBS comprising various amounts of the recombinant HA protein of antigenic H5 type (200 ng, 100 ng and 50 ng) and a significant excess of other "nonantigenic" proteins such as transferrin (5 μg), fetuin (5 μg) and ribonuclease (1 μg). The abundance of the HA protein (1.8-0.5%, w/w) was purposely low to test the extraction efficiency of the AbH5N2@Fe3O4 MNPs. After enrichment of HA proteins, the HA-MNP complex was mixed with sinapinic acid (SA), a MALDI matrix, and directly subjected to MALDI-MS analysis.
Although the antibody-antigen complexes have strong interactions with dissociation constants (Kd) ranging from 10-7 to 10-11 M, most antibody-antigen complexes can still be dissociated at extreme pH (i.e., pH < 2 or pH > 12). The SA matrix solution used for MALDI-MS analysis has a low pH (< 2) and thus may directly elute the antigen bound to the antibody-conjugated MNPs on the MALDI sample plate.
The affinity extraction of HA protein from a complex mixture was very efficient using the antibody-conjugated MNPs, as even a minute amount (50 ng) of HA protein was visible (Figure 3E). Assuming full recovery of all the HA protein (50 ng) present in the solution, the absolute detection limit was estimated to be 0.7 pmol (9 nM).
• Isolation of HA proteins from a virus sample for electrophoresis and mass spectrometric analyses
To evaluate the assay sensitivity, AbH5N2@Fe3O4 MNPs (10 μg) were incubated with different amounts (0.05-1 μL) of the 1000-fold diluted H5N2 virus lysate (~107.8 EID50/mL, Figure 5B). As low as 0.1 μL of virus lysate, corresponding to ~103.8 EID50 of H5N2 viruses, was detected by SDS-PAGE using silver staining for visualization (Figure 5B, line 4).
• Differentiation of influenza virus subtypes
We have demonstrated a facile method for the detection of H5N2 influenza virus using aminosilane coated iron oxide nanoparticles with surface functionalization of monoclonal antibodies specific to the HA protein in H5N2. Through simple magnetic separation, the AbH5N2@Fe3O4 MNPs showed effective isolation of H5N2 viruses from lysate for direct MALDI-TOF MS readout without the need for a tedious elution step. The detection limit was in the range of ~104 EID50 by SDS-PAGE or ~103 EID50 by MALDI-TOF MS. Our study demonstrated that the combined use of antibody-MNPs and MALDI-MS was suitable for sensitive detection of influenza viruses. Although the direct quantitative comparison of our method with other previously reported diagnostic methods is difficult because each method characterizes a specific property of the virus under various conditions, our present method appears to provide comparable or better sensitivity in the detection of influenza virus than commercially available kits [8, 10]. These kits have a limit of detection in the range of 104.5-105.5 TCID50 or 104.7 ELD50. Therefore, the method presented here can be utilized for the rapid screening of virus subtypes. The overall workflow of our method for influenza virus detection including virus lysis, magnetic separation and MALDI-TOF MS measurement can be routinely completed in one hour. We also demonstrated, for the first time, that the nanoprobe-based detection unambiguously differentiated the H5N2 virus from other closely related antigenic subtypes of (recombinant) H5N1 viruses in a highly specific manner.
With the automatic readout of MALDI-TOF MS, our method has the potential for integration into high-throughput virus assays, suggesting a promising application in early and accurate diagnosis of influenza viruses. Given the increasing use of virus screening assays, our current assay offers a flexible design for immobilization of other virus-specific molecular probes on a nanoparticle surface for diverse applications.
All of the chemicals were of reagent grade unless indicated otherwise. Ferrous chloride tetrahydrate (FeCl2.4H2O), ferric chloride (FeCl3), tetraethyl orthosilicate (TEOS), 3-aminopropyltrimethoxysilane (APS), 1-propanol, ammonia solution (28%), and dimethyl sulfide were purchased from Acros. Suberic acid bis-N-hydroxysuccinimide ester (DSS), 2-bromoethylamine hydrobromide (BEI), sodium carbonate, silver nitrate, α-cyano-4-hydroxycinnamic acid (CHCA), and sinapinic acid (SA) were purchased from Sigma-Aldrich. Formalin, methanol, acetonitrile (HPLC grade), and trifluoroacetic acid (TFA) were purchased from Merck. Acetic acid and sodium thiosulfate were purchased from J. T. Baker. All the chemicals were used as received without further purification. A homemade magnet was used in the separation of magnetic nanoparticles.
The HA proteins of H5 type were prepared using the H5 consensus sequence previously described . The 1 × PBS buffer (pH 7.4, GIBCO) contained NaCl (137 mM), KCl (2.7 mM), KH2PO4 (1.5 mM) and Na2HPO4 (8.1 mM). The 1 × RIPA buffer (pH 8.0) contained Tris-HCl (50 mM, Amersham Bioscience), NaCl (150 mM), NP-40 (1%, Calbiochem), sodium deoxycholate (0.5%, Sigma) and sodium dodecyl sulfate (0.1%, USB). The 2 × RIPA buffer (pH 8.0) contained Tris-HCl (50 mM), NaCl (150 mM), NP-40 (2%), sodium deoxycholate (1%) and sodium dodecyl sulfate (0.1%). The TEN buffer (pH 7.5) contained Tris-HCl (50 mM, pH 7.5), EDTA (pH 8.0, 1.3 mM) and NaCl (100 mM).
Transmission electron microscopy (TEM) images were obtained on a Hitachi H-7100 Transmission Electron Microscope. Powder X-Ray Diffraction (XRD) was recorded by PANalytical X' Pert PRO. The magnetic effect was measured on a superconducting quantum interference device magnetometer (SQUID, Quantum Design MPMS7). LC-MS/MS spectra were recorded on a Waters Q-TOF™ Premier mass spectrometer (Waters Corp, Milford, MA). MALDI-TOF MS analyses were performed using an Applied Biosystems 4800 mass spectrometer (Applied Biosystems, Foster City, USA) equipped with a Nd-YAG laser (355 nm).
• Preparation of virus
The supernatant (0.2 mL/egg) of H5N2 influenza virus A/duck/Yunlin/04 (H5N2) was inoculated to the allantoic cavity of 9 to 11-day-old specific pathogen-free (SPF) embryonated hens' eggs, which were then cultivated in an incubator. The eggs that died within 24 h were discarded. Other eggs were incubated at 4°C for another 4 h to contract blood vessels. The allantoic fluid was then collected by needle and stored at -80°C.
To separate the cell lysate, the allantoic fluid was frozen and thawed several times to rupture the cells. The solution was subjected to centrifugation (3000 rpm, Centrifuge 5804R, Eppendorf, Germany) at 4°C for 15 min. The supernatant was treated with 1% BEI at 37°C for 18 h to inactivate the virus. After centrifugation (70, 000 × g, Avanti J-25 Centrifuge, Beckman) at 4°C, the virus pellets were collected, dissolved in TEN buffer, and stored overnight at 4°C. The virus was then separated by centrifugation (50, 000 rpm, Optima MAX-E Ultracentrifuge, Beckman) in a sucrose gradient (20-50%) at 4°C for 2 h. The concentrated H5N2 virus solution in TEN buffer was estimated to have an EID50 (50% egg infectious dose) value of about 1010.8 per mL, corresponding to ~1011 particles/mL estimated using the TEM-imaging of a mixture of viruses and a known concentration of polystyrene latex beads (137 nm in diameter) .
The recombinant H5N1 viruses RG5 (A/Anhui/1/2005), RG23 (A/turkey/Turkey/01/2003) and NIBRG14 (A/Vietnam/1194/2004) were obtained from Dr. Jia-Tsrong Jan (The Genomics Research Center, Academia Sinica) . The TCID50 (50% tissue culture infectious dose) on Madin-Darby canine kidney (MDCK) cells was estimated to be around 3 × 106 (RG5), 1 × 105 (RG23), and 3 × 106 (NIBRG14) per mL, respectively, according to the Reed-Muench method .
• Preparation of antibody
The monoclonal antibodies against A/duck/Yunlin/04 (H5N2) virus were purchased from LTK BioLaboratories (Taipei, Taiwan) and purified on an immunoglobin affinity column. Briefly, a protein A HiTrap affinity column (Pharmacia biotech, Orsay, France) was activated with binding buffer (20 mM sodium phosphate buffer, pH 7.0). The ascites (1 mL) were mixed with Tris-HCl (200 μL of 1 M solution, pH 9.0) and applied to the affinity column. After the turbid impurities were washed off with binding buffer (10 × column volume), a striping buffer (700 μL of 0.1 M citric acid, pH 3.0) was applied to elute the antibodies. The collected antibody solution was then dialyzed in 1 L of PBS buffer (0.1 M) and stored at -20°C. The content of antibody protein (3 × 103 μg/mL) was measured by the Bradford method .
• Preparation of aminosilane coated iron oxide magnetic nanoparticles
Iron oxide nanoparticles (Fe3O4) were synthesized using FeCl2 and FeCl3 under basic conditions according to the previously reported method . The freshly prepared Fe3O4 nanoparticles (30 mg) were suspended in 1-propanol (80 mL) and sonicated for 40 min at room temperature. Next, NH4OH (28% w/w, 8.94 mL), ddH2O (7.5 mL), and TEOS (0.1 mL) were slowly added to the above solution, and the mixture was stirred at 40°C for 2 h. APS (0.1 mL) was injected into the solution and the mixture was stirred for another 1 h. The blackish precipitates were collected with a magnet and washed with 1-propanol to give the aminosilane coated iron oxide magnetic nanoparticles (AS@Fe3O4 MNP).
• Synthesis of antibody conjugated magnetic nanoparticles
AS@Fe3O4 MNPs (0.5 mg) were suspended in DMSO (125 μL) and sonicated for 30 min at room temperature. DSS (5 mg) was added to the solution and the mixture was stirred at room temperature for 1 h. The precipitates were separated by magnet and washed with DMSO (250 μL) three times. The antibody (15 μL) was added at 4°C. After 1 h, a blocking reagent, 3, 6, 9-trioxadecylamine (a methoxy-terminated ethylene glycol amine, MEGA, 35 μL of 30 mM solution in DMSO), was added to the mixture. The mixture was stirred for another 18 h at 4°C, and the precipitates were collected by magnet. After washing with PBS, the antibody conjugated nanoparticles (AbH5N2@Fe3O4 MNP) were re-dissolved in PBS (50 μL) and stored at 4°C. By a similar procedure but without the addition of antibody, the ethylene glycol encapsulated nanoparticles MEGA@Fe3O4 MNP were prepared and used as the control in experiments.
• Incubation of AbH5N2@Fe3O4 MNP with viruses
Concentrated H5N2 virus solution (2 μL of 1.03 × 103 μg/mL in TEN buffer) was incubated with 2 × RIPA buffer (57 μL) at 25°C for 1 h. An aliquot (1 μL) of AbH5N2@Fe3O4 MNP (0.5 mg in 50 μL of 1 × PBS) was added to the virus solution and incubated for 30 min. The HA-MNP complexes were then isolated by magnet and washed with 1 × RIPA buffer for the subsequent SDS-PAGE and MALDI-TOF MS analyses.
• SDS-PAGE analysis of HA-nanoparticle conjugates
The above-prepared HA-MNP complexes were resuspended in sample buffer containing 50 mM Tris-HCl (pH 6.8), SDS (1%, w/v), glycerol (10%, v/v), bromophenol blue (0.01%, w/v), and 0.7 M β-mercaptoethanol, and then heated at 95°C for 5 min. The sample was then separated on 10% SDS-PAGE gel in a running buffer containing Tris (0.3%, w/v), glycine (1.2%, w/v) and SDS (0.1%, w/v). Visualization of the protein bands was performed by silver staining. The SDS-PAGE was fixed with a solution containing 50% methanol, 12% acetic acid and 0.05% formalin for at least 2 h. The gel was washed three times with 35% ethanol for 20 min and soaked in a sensitizer solution (0.02% sodium thiosulfate) for 2 min. The gel was washed three times with deionized water and then incubated with a staining buffer containing silver nitrate (0.2%, w/v) and formalin (0.076%) in the dark for 20 min. The gel was then washed twice with deionized water. The band images were developed in a 50 mL solution containing sodium carbonate (6%, w/v), sodium thiosulfate (0.0004%, w/v) and formalin (0.05%). The silver reduction was processed for about 2 min until the expected intensity of protein was reached. Image development was terminated by treatment with a stop solution containing acetic acid (12%) and methanol (50%) for 5 min, then stored at 4°C in 1% acetic acid.
• Protein digestion and LC-MS/MS analysis
After electrophoresis, the band at ~45 kDa, corresponding to the HA1 protein, was taken from the SDS-PAGE gel and cut into small pieces (1 mm3). The gel slices were washed with 25 mM ammonium bicarbonate and 50% acetonitrile, reduced with 10 mM dithiothreitol, and then alkylated with 55 mM iodoacetamide. Trypsin (protein/trypsin = 20:1, g/g) was used to digest the protein by incubation for 12 h at 37°C. The resulting peptides were extracted with acetonitrile/TFA (50%/0.1%) and then acetonitrile. The peptide solution was concentrated on a SpeedVac and reconstituted in 8 L of 0.1% TFA aqueous solution (buffer A).
For protein identification by LC-MS/MS, the digested peptides were injected into a capillary trap column (2 cm × 180 μm) and separated on a BEH C18 column (25 cm × 75 mm × 1.7 mm, Waters ACQUITY, Milford, MA). The column was maintained at 35°C and the bound peptides were eluted with a linear gradient of 0-80% buffer B/A (buffer A, 0.1% TFA in H2O; buffer B, 0.1% TFA in acetonitrile) for 80, 120, 180, 210 and 270 minutes. MS was operated in ESI positive V mode with a resolving power of 10, 000. NanoLockSpray source was used for accurate mass measurement and the lock mass channel was sampled every 30 seconds. The mass spectrometer was calibrated with a synthetic human [Glu1]-Fibrinopeptide B solution (1 pmol/μL, from Sigma-Aldrich) delivered through the NanoLockSpray source. Data acquisition was operated in the data directed analysis (DDA) mode. The method included a full MS scan (m/z 400-1600, 0.6 seconds) and three MS/MS scans (m/z 100-1990, 1.2 seconds each scan) sequentially on the three most intense ions present in the full scan mass spectrum. The identification of peptide sequences was performed by database searching of MS/MS spectra using the Mascot algorithm (v2.1.0, Matrix Science, London, UK) against the NCBI database. The peak lists in the MS/MS spectra were extracted from Analyst QS 1.1 (Applied Biosystems) software with the default charge state set to 2+, 3+, and 4+. Search parameters for peptide and MS/MS mass tolerance were ± 0.3 and ± 0.1 Da, respectively, with allowance for two missed cleavages from the trypsin digest and variable modifications of carbamidomethyl (Cys) and oxidation (Met). Peptides were considered confidently identified if their Mascot individual ion scores were higher than the Mascot identity scores (p < 0.05).
• MALDI-TOF MS analysis
The sample of H5N2 virus enriched by trapping with AbH5N2@Fe3O4 MNPs was mixed with fresh sinapinic acid (10 g/L) in a 1:1 (v/v) ratio. The complex was directly deposited onto the sample plate, dried in air, and then subjected to analysis on a 4800 MALDI TOF/TOF MALDI-TOF/TOF mass spectrometer (Applied Biosystems, Foster City, CA). To obtain a stable signal, a typical mass spectrum was constructed by averaging 1800 laser shots followed by noise reduction and Gaussian smoothing using Data-Explorer software (Applied Biosystems). The MALDI-TOF MS analysis was acquired with an Nd-YAG laser (355 nm) operating at a repetition rate of 200 Hz. The spectra were recorded in the linear mode using an accelerating voltage of 20 kV, a 19% grid voltage, a low-mass gate of 10 kDa, and a 630 ns delay time. The protein mixture of cytochrome c (12361 Da) and myoglobin (16952 Da) was used as an external mass calibration reference.
We thank the National Science Council and the Council of Agriculture, Taiwan, for financial support and thank Dr. Che Alex Ma and Dr. Jia-Tsrong Jan (The Genomics Research Center, Academia Sinica) for their gifts of HA proteins and recombinant H5N1 viruses.
- Wilson IA, Skehel JJ, Wiley DC: Structure of the hemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution. Nature. 1981, 289: 366-373. 10.1038/289366a0.View ArticleGoogle Scholar
- Wilson IA, Cox NJ: Structural basis of immune recognition of influenza virus hemagglutinin. Annu Rev Immunol. 1990, 8: 737-771. 10.1146/annurev.iy.08.040190.003513.View ArticleGoogle Scholar
- Moscona A: Neuraminidase Inhibitors for Influenza. N Engl J Med. 2005, 353: 1363-1373. 10.1056/NEJMra050740.View ArticleGoogle Scholar
- De Clercq E: Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006, 5: 1015-1025. 10.1038/nrd2175.View ArticleGoogle Scholar
- Lagoja IM, De Clercq E: Anti-influenza virus agents: synthesis and mode of action. Med Res Rev. 2008, 28: 1-38. 10.1002/med.20096.View ArticleGoogle Scholar
- World Health Organization: Recommendations and laboratory procedures for detection of avian influenza A(H5N1) virus in specimens from suspected human cases. 2007, [http://www.who.int/influenza/resources/documents/h5n1_laboratory_procedures/en/]Google Scholar
- Quan PL, Briese T, Palacios G, Lipkin WI: Rapid sequence-based diagnosis of viral infection. Antiviral Res. 2008, 79: 1-5. 10.1016/j.antiviral.2008.02.002.View ArticleGoogle Scholar
- Evaluation of rapid influenza diagnostic tests for detection of novel influenza A (H1N1) virus - United States. CDC Morbidity and Mortality Weekly Report. 2009, 58: 826-829. [http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5830a2.htm?s_cid]
- Vinikoor M, Stevens J, Nawrocki J, Singh K: Influenza A virus subtyping: paradigm shift in influenza diagnosis. J Clin Microbiol. 2009, 47: 3055-3056. 10.1128/JCM.01388-09.View ArticleGoogle Scholar
- Woolcock PR, Cardona CJ: Commercial immunoassay kits for the detection of influenza virus type A: evaluation of their use with poultry. Avian Dis. 2005, 49: 477-481. 10.1637/7357-031605R.1.View ArticleGoogle Scholar
- Zhang A, Jin AM, Liu F, Guo X, Hu Q, Han L, Tan Y, Chen H: Development and evaluation of a DAS-ELISA for rapid detection of avian influenza viruses. Avian Dis. 2006, 50: 325-330. 10.1637/7473-111605R.1.View ArticleGoogle Scholar
- He Q, Velumani S, Du Q, Chee WL, Fook KN, Donis R, Kwang J: Detection of H5 avian influenza viruses by antigen-capture enzyme-linked immunosorbent assay using H5-specific monoclonal antibody. Clin Vaccine Immunol. 2007, 24: 617-623.View ArticleGoogle Scholar
- Chen YC, Chen CH, Wang CH: H5 antibody detection by blocking enzyme-linked immunosorbent assay using a monoclonal antibody. Avian Dis. 2008, 52: 124-129. 10.1637/8076-071807-Reg.View ArticleGoogle Scholar
- Mandenius CF, Wang R, Aldén A, Bergström G, Thébault S, Lutsch C, Ohlson S: Monitoring of influenza virus hemagglutinin in process samples using weak affinity ligands and surface plasmon resonance. Anal Chim Acta. 2008, 623: 66-75. 10.1016/j.aca.2008.06.005.View ArticleGoogle Scholar
- Yan X, Zhong W, Tang A, Schielke EG, Hang W, Nolan JP: Multiplexed flow cytometric immunoassay for influenza virus detection and differentiation. Anal Chem. 2005, 77: 7673-7678. 10.1021/ac0508797.View ArticleGoogle Scholar
- Liu S, Chen G, Zhou Q, Wei Y: An immuno-biosensor system based on quartz crystal microbalance for avian influenza virus detection. Proc SPIE. 2008, 67943P-Google Scholar
- Kiselar JG, Downard KM: Antigenic surveillance of the influenza virus by mass spectrometry. Biochemistry. 1999, 38: 14185-14191. 10.1021/bi991609j.View ArticleGoogle Scholar
- Downard KM, Morrissey B, Schwahn AB: Mass spectrometry analysis of the influenza virus. Mass Spect Rev. 2009, 28: 35-49. 10.1002/mas.20194.View ArticleGoogle Scholar
- Schwahn AB, Wong WH, Downard KM: Subtyping of the influenza virus by high resolution mass spectrometry. Anal Chem. 2009, 81: 3500-3506. 10.1021/ac900026f.View ArticleGoogle Scholar
- Townsend MB, Dawson ED, Mehlmann M, Smagala JA, Dankbar DM, Moore CL, Smith CB, Cox NJ, Kuchta RD, Rowlen KL: Experimental evaluation of the FluChip diagnostic microarray for influenza virus surveillance. J Clin Microbiol. 2006, 44: 2863-2871. 10.1128/JCM.00134-06.View ArticleGoogle Scholar
- Dawson ED, Moore CL, Dankbar DM, Mehlmann M, Townsend MB, Smagala JA, Smith CB, Cox NJ, Kuchta RD, Rowlen KL: Identification of A/H5N1 influenza viruses using a single gene diagnostic microarray. Anal Chem. 2007, 79: 378-384. 10.1021/ac061920o.View ArticleGoogle Scholar
- Wang LC, Pan CH, Severinghaus LL, Liu LY, Chen CT, Pu CE, Huang D, Lir JT, Chin SC, Cheng MC, Lee SH, Wang CH: Simultaneous detection and differentiation of Newcastle disease and avian influenza viruses using oligonucleotide microarrays. Vet Microbiol. 2008, 127: 217-226. 10.1016/j.vetmic.2007.08.019.View ArticleGoogle Scholar
- Maines TR, Jayaraman A, Belser JA, Wadford DA, Pappas C, Zeng H, Gustin KM, Pearce MB, Viswanathan K, Shriver ZH, Raman R, Cox NJ, Sasisekharan R, Katz JM, Tumpey TM: Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science. 2009, 325: 484-487.Google Scholar
- Childs RA, Palma AS, Wharton S, Matrosovich T, Liu Y, Chai W, Campanero-Rhodes MA, Zhang Y, Eickmann M, Kiso M, Hay A, Matrosovich M, Feizi T: Receptor-binding specificity of pandemic influenza A (H1N1) 2009 virus determined by carbohydrate microarray. Nat Biotechnol. 2009, 27: 797-799. 10.1038/nbt0909-797.View ArticleGoogle Scholar
- Wang CC, Chen JR, Tseng YC, Hsu CH, Hung YF, Chen SW, Chen CM, Khoo KH, Cheng TJ, Cheng YS, Jan JT, Wu CY, Ma C, Wong CH: Glycans on influenza hemagglutinin affect receptor binding and immune response. Proc Natl Acad Sci USA. 2009, 106: 18137-18142. 10.1073/pnas.0909696106.View ArticleGoogle Scholar
- Liao HY, Hsu CH, Wang SC, Liang CH, Yen HY, Su CY, Chen CH, Jan JT, Ren CT, Chen CH, Cheng TJR, Wu CY, Wong CH: Differential receptor binding affinities of influenza hemagglutinins on glycan arrays. J Am Chem Soc. 2010, 132: 14849-14856. 10.1021/ja104657b.View ArticleGoogle Scholar
- Hutchens TW, Yip TT: New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun Mass Spectr. 1993, 7: 576-580. 10.1002/rcm.1290070703.View ArticleGoogle Scholar
- Nelson RW, Krone JR, Bieber AL, Williams P: Mass spectrometric immunoassay. Anal Chem. 1995, 67: 1153-1158. 10.1021/ac00103a003.View ArticleGoogle Scholar
- Nedelkov D, Tubbs KA, Niederkofler EE, Kiernan UA, Nelson RW: High-throughput comprehensive analysis of human plasma proteins: a step toward population proteomics. Anal Chem. 2004, 76: 1733-1737. 10.1021/ac035105+.View ArticleGoogle Scholar
- Nedelkov D, Kiernan UA, Niederkofler EE, Tubbs KA, Nelson RW: Investigating diversity in human plasma proteins. Proc Natl Acad Sci USA. 2005, 102: 10852-10857. 10.1073/pnas.0500426102.View ArticleGoogle Scholar
- Hsing IM, Xu Y, Zhao W: Micro- and nano-magnetic particles for applications in biosensing. Electroanalysis. 2007, 19: 755-768. 10.1002/elan.200603785.View ArticleGoogle Scholar
- Gupta AK, Naregalkar RR, Vaidya VD, Gupta M: Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Nanomedicine. 2007, 2: 23-39. 10.2217/17435822.214.171.124.View ArticleGoogle Scholar
- Sun C, Lee JSH, Zhang M: Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Delivery Rev. 2008, 60: 1252-1265. 10.1016/j.addr.2008.03.018.View ArticleGoogle Scholar
- Jun YW, Lee JH, Cheon J: Chemical design of nanoparticle probes for high-performance magnetic resonance imaging. Angew Chem Int Ed. 2008, 47: 5122-5135. 10.1002/anie.200701674.View ArticleGoogle Scholar
- McCarthy JR, Weissleder R: Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Delivery Rev. 2008, 60: 1241-1251. 10.1016/j.addr.2008.03.014.View ArticleGoogle Scholar
- Chou PH, Chen SH, Liao HK, Lin PC, Her GR, Lai ACY, Chen JH, Lin CC, Chen YJ: Nanoprobe-based affinity mass spectrometry for selected protein profiling in human plasma. Anal Chem. 2005, 77: 5990-5997. 10.1021/ac050655o.View ArticleGoogle Scholar
- Lin PC, Chou PH, Chen SH, Liao HK, Wang KY, Chen YJ, Lin CC: Ethylene glycol-protected magnetic nanoparticles for a multiplexed immunoassay in human plasma. Small. 2006, 2: 485-489. 10.1002/smll.200500387.View ArticleGoogle Scholar
- Lin PC, Tseng MC, Su AK, Chen YJ, Lin CC: Functionalized magnetic nanoparticles for small-molecule isolation, identification, and quantification. Anal Chem. 2007, 79: 3401-3408. 10.1021/ac070195u.View ArticleGoogle Scholar
- Wang KY, Chuang SA, Lin PC, Huang LS, Chen SH, Ouarda S, Pan WH, Lee PY, Lin CC, Chen YJ: Multiplexed immunoassay: quantitation and profiling of serum biomarkers using magnetic nanoprobes and MALDI-TOF MS. Anal Chem. 2008, 80: 6159-6167. 10.1021/ac800354u.View ArticleGoogle Scholar
- Kang YS, Risbud S, Rabolt JF, Stroeve P: Synthesis and characterization of nanometer-size Fe3O4 and γ-Fe2O3 particles. Chem Mater. 1996, 8: 2209-2211. 10.1021/cm960157j.View ArticleGoogle Scholar
- Chen YC, Chen CH, Wang CH: H5 antibody detection by blocking enzyme-linked immunosorbent assay using a monoclonal antibody. Avian Dis. 2008, 52: 124-129. 10.1637/8076-071807-Reg.View ArticleGoogle Scholar
- Schreyeck L, Wlosik A, Fuzellier H: Influence of the synthesis route on MgAl2O4 spinel properties. J Mater Chem. 2001, 11: 483-486. 10.1039/b005215i.View ArticleGoogle Scholar
- Webster RG: Estimation of the molecular weights of the polypeptide chains from the isolated hemagglutinin and neuraminidase subunits of influenza viruses. Virology. 1970, 40: 643-654. 10.1016/0042-6822(70)90209-6.View ArticleGoogle Scholar
- Schulze IT: The biologically active proteins of influenza virus: the hemagglutinin. The influenza virus and influenza. Edited by: Kilbourne ED. 1975, Academic Press, New-York, 53-83.Google Scholar
- Skehel JJ, Waterfield MD: Studies on the primary structure of the influenza virus hemagglutinin. Proc Natl Acad Sci USA. 1975, 72: 93-97. 10.1073/pnas.72.1.93.View ArticleGoogle Scholar
- Chen MW, Cheng TJR, Huang Y, Jan JT, Ma SH, Yu AL, Wong CH, Ho DD: A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc Natl Acad Sci USA. 2008, 105: 13538-13543. 10.1073/pnas.0806901105.View ArticleGoogle Scholar
- Zheng YZ, Webb R, Greenfield PF, Reid S: Improved method for counting virus and virus like particles. J Virol Methods. 1996, 62: 153-159. 10.1016/S0166-0934(96)02100-3.View ArticleGoogle Scholar
- Reed LJ, Muench H: A simple method of estimating fifty percent endpoints. Am J Hyg. 1938, 27: 493-497.Google Scholar
- Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976, 72: 248-254. 10.1016/0003-2697(76)90527-3.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.